The Thoracic Surgery team at Ruijin Hospital, led by Prof. Hecheng Li, has successfully performed Shanghai’s first segmentectomy using the SHURUI® single-port robotic system—marking a new milestone in precision thoracic surgery.
The 67-year-old patient presented with a growing solid nodule in the left lower lobe. PET-CT imaging indicated a high risk of malignancy (SUVmax 8.6). After multidisciplinary consultation and 3D reconstruction, the team opted for a targeted subsegmental resection (L-S6a) using the SHURUI® platform to preserve as much healthy lung tissue as possible.
On June 3, the surgery was completed through a single 3.5 cm intercostal incision in just 30 minutes, with minimal bleeding (20 ml). The patient recovered well and was discharged on postoperative day three.
This achievement underscores Ruijin’s expanding leadership in minimally invasive robotic surgery. The team is now advancing SHURUI® surgical system’s integration across campuses to deliver ultra-precise, low-impact care to a broader patient population.
Important Notes
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.
